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In this issue of the Journal, van der Marel et al.1 report a case of pure red cell aplasia(PRCA) and hypogammaglobulinemia complicating a thymoma. After surgical resection
of the thymoma, the patient experienced hematopoietic recovery but required ongoing
treatment with replacement gamma globulin. This case illustrates two rare paraneoplastic
syndromes that can be associated with a thymoma.
An association between thymomas and various paraneoplastic syndromes is well
recognized, with the most common paraneoplastic syndrome being myasthenia gravis
(MG), occurring in 30% to 46% of patients with a thymoma.2,3 There are at least 20 other
syndromes that have been reported in association with thymoma, including PRCA,
hypogammaglobulinemia, and a wide range of autoimmune disorders. More than 40% of
patients with thymoma are afflicted with a so-called parathymic syndrome.4 This com-
mentary focuses on the diagnosis and management of PRCA in association with a
thymoma.
Among patients with thymoma, fewer than 10% will develop PRCA, whereas fewer
than 5% of patients with PRCA have a thymoma. Other known associations with PRCA
include medications such as erythropoietin, viral infections including parvovirus, immune
disorders, ABO-incompatible hematopoietic stem cell or bone marrow transplantation,
and other malignancies. PRCA can also present as a primary, idiopathic disease.5
PRCA is characterized by erythropoietic failure with preserved granulopoiesis and
megakaryopoiesis. The diagnosis should be suspected in a patient with isolated anemia
and absent reticulocytes and be confirmed with a bone marrow biopsy, which classically
shows a selective decrease in erythroid precursors without other diagnostic morphological
abnormalities.
The pathophysiology of PRCA and thymoma is not entirely understood, but it seems
to be related to an autoimmune mechanism. In some cases, there has been evidence for
antibodies against erythroblasts blocking differentiation of erythroid progenitors; antibod-
ies directed against native erythropoietin blocking signaling by that cytokine; or cell-
mediated suppression of erythropoiesis by autoreactive T cells, large granular lympho-
cytes, or natural killer cells. In cases of drug- or virus-induced PRCA, a direct toxic effect
of a virus or drug on erythroid precursors is suspected.5–7
Because of the rarity of PRCA in association with thymoma, there are no standard
treatment guidelines. At the time of diagnosis, surgical resection of the thymoma is
usually undertaken. Some patients experience restoration of normal hematopoiesis after
resection of the thymoma, as demonstrated in the case presented in this issue.1 It has been
reported that removal of the thymoma leads to remission of PRCA in 25% to 30% of
cases,8 but modern series have suggested remission from surgery alone is actually quite
rare and that most patients will require some other form of therapy.9
Multiple non-surgical interventions have been attempted in patients with PRCA and
thymoma, including systemic corticosteroids, other immunosuppressant drugs, chemo-
therapy, androgens, splenectomy, and monoclonal antibodies. In our case series of 13
patients, cyclosporine and anti-thymocyte globulin (ATG) were the most effective
treatments in achieving transfusion independence.9 However, complications from therapy,
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particularly infections, were common. Several patients had
hypogammaglobulinemia associated with their clinical syn-
drome, which increased their risk of infection. Thrombotic
thrombocytopenic purpura developed in two patients treated
with cyclosporine. Therefore, side effects of treatment are
common, and caution should be exercised when treating these
patients.
When faced with a patient with a new diagnosis of
anemia in conjunction with a thymoma, PRCA should be
considered. Evaluation should include a peripheral reticulo-
cyte count; if there is reticulocytopenia, a bone marrow
biopsy is prudent. Before surgical resection of the thymoma,
the possibility of occult myasthenia gravis should be consid-
ered because this syndrome is seen so commonly in associ-
ation with a thymoma and may have implications for delivery
of appropriate anesthesia and perioperative care. Once PRCA
has been diagnosed, blood counts and reticulocyte counts
should be monitored carefully, and if erythropoiesis does not
return within 4 to 6 weeks postoperatively, systemic cortico-
steroids should be initiated. Standard therapy is prednisone,
typically at a dose of 1 mg/kg by mouth daily, with plans to
treat at full doses for approximately 4 weeks. If the patient
remains transfusion-dependent despite steroid therapy, a rea-
sonable next step would be initiation of ATG and cyclospor-
ine. Cyclosporine trough blood levels need to be monitored to
avoid toxicity. Once reticulocytosis has been restored, pred-
nisone can be slowly tapered. If the patient remains stable,
cyclosporine may also be discontinued. Other options for
patients whose disease is refractory to these measures include
alternative immunosuppressants, cyclophosphamide, or an-
drogens. Monoclonal antibodies such as rituximab and ale-
mtuzumab have been reported to be effective therapies in
case reports of patients with PRCA, even in refractory dis-
ease, but there have been no reported cases of their use in
patients with PRCA and thymoma.10
In summary, paraneoplastic syndromes are commonly
seen in association with thymomas. Myasthenia gravis is the
most common, followed by PRCA, hypogammaglobuline-
mia, and other autoimmune phenomena. PRCA seems to be
caused by an autoimmune mechanism, and treatment ap-
proaches target the immune system. Initial therapy is surgical
removal of the thymoma, but most patients will require
additional treatments such as prednisone, ATG, and cyclo-
sporine to restore erythropoiesis.
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